O Toxoplasma gondii é conhecido por infectar um número considerável de espécies de mamíferos e aves e uma proporção substancial da população humana mundial. O parasita tem uma capacidade impressionante de se disseminar no corpo do hospedeiro e emprega várias tácticas para ultrapassar a barreira hemato-encefálica altamente reguladora e residir no cérebro. Em indivíduos saudáveis, a infecção por T. gondii é largamente tolerada sem quaisquer efeitos nocivos óbvios. No entanto, a infecção primária em doentes imunodeprimidos pode resultar em doença cerebral ou sistémica aguda, e a reactivação de quistos tecidulares latentes pode levar a um resultado mortal. É imperativo que o tratamento da encefalite toxoplásmica com risco de vida seja atempado e eficaz.
Introdução
O que você precisa saber de cara
Linfoma primário do SNC é um tipo raro de câncer que se origina diretamente no cérebro, medula espinhal ou olhos. Geralmente afeta pessoas com sistema imunológico comprometido, mas pode ocorrer em indivíduos saudáveis.
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Nenhum gene associado encontrado
Os dados genéticos desta condição ainda estão sendo catalogados.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Linfoma primário do sistema nervoso central
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
20 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 1.864
The Regulation of Vasomotor and Cardiorespiratory Pulsations Is Disrupted in Primary Central Nervous System Lymphoma: A Case-Control fMRI Study.
Primary central nervous system lymphoma (PCNSL) alters (peri)vascular structures while increasing vasomotor and cardiorespiratory pulsations within the brain. Vasomotor pulsations may arise from amplitude modulations of respiratory (RPE) and cardiovascular (CHE) pulsations while cardiovascular fluctuations may be modulated by respiration through cardiorespiratory amplitude modulation (CREM). In this study, we examined glymphatic cerebrospinal fluid convection in brains of PCNSL patients by assessing these waves. Thirty PCNSL patients (median 66y; 9 females) and 40 healthy age-matched controls (median 62y; 29 females) were scanned using an fMRI-based MREGBOLD sequence. Respective MREGBOLD fluctuation amplitudes (AFRPE; AFCHE; AFCREM) were compared between groups using nonparametric permutation. Regional amplitudes were compared using Mann-Whitney analysis and Cox survival analysis. Subject-specific pulsations were analyzed through Z-score mapping. AFCREM and AFRPE were significantly elevated across PCNSL brains, with lesser increases in AFCHE. However, only significant increases in AFRPE remained after correcting for sex and head displacement. AFRPE showed a link to mortality as it was markedly elevated in deceased patients. While elevations in all pulsations were present within (peri)tumoral regions, AFRPE elevations extended into extra-tumoral white matter and grey matter. Thus, altered cardiorespiratory fluctuations give rise to dysfunctional vasomotor and CSF pulsations in PCNSL, predicting impaired glymphatic function.
KPT-8602 combined with IFN-γ released ZBP1-PANoptosome to inhibit the progression of primary central nervous system lymphoma.
To investigate whether the combination of KPT-8602 and interferon-γ (IFN-γ) can inhibit the progression of primary central nervous system lymphoma (PCNSL) by activating ZBP1-mediated PANoptosis. Human lymphoma cell lines including Raji (Burkitt's lymphoma) and U-2932 (Diffuse large B-cell lymphoma, DLBCL) were employed. The synergistic induction of PANoptosis by KPT-8602 and IFN-γ was evaluated using CCK8 assay, flow cytometry, YO-PRO/PI staining, and Western blot analysis. A mouse model of PCNSL was established through stereotaxic brain implantation. The efficacy and molecular mechanisms of the combined therapy were evaluated using HE staining, TUNEL staining, ELISA, multiplex immunofluorescence, and Western blot analysis. The combination therapy of KPT-8602 and IFN-γ exhibited synergistic inhibitory effects on lymphoma cell growth (CI < 1). The combination therapy group significantly enhanced apoptosis and PANoptosis, as well as upregulated the mRNA levels of PANoptosis-related inflammatory factors (IL-18, IL-1β) and the expression of PANoptosis-associated proteins. In the nude mouse model, the tumor volume was significantly smaller in the combination therapy group compared to the single-drug group. Additionally, there was a notable increase of TUNEL staining positivity in tumor tissue and elevated levels of the inflammatory factors IL-6 and CXCL13 in the cerebrospinal fluid. The Western blot analysis of tumor tissue was consistent with in vitro experiments, demonstrating significant activation of the PANoptosis pathway. The combination of KPT-8602 and IFN-γ can activate the pan-apoptotic pathway by upregulating ZBP1, thereby effectively inhibiting the growth of PCNSL. This study presented a promising new combination treatment strategy for PCNSL.
A case report: primary central nervous system lymphoma misdiagnosed as neuromyelitis optica.
Primary central nervous system lymphoma (PCNSL) occurring in the spinal cord is very rare. Due to its atypical clinical symptoms and imaging manifestations, it is extremely easy to be misdiagnosed as other diseases. This study reports a case of PCNSL misdiagnosed as neuromyelitis optica (NMO) and analyses neuroimaging characteristics that may aid in the diagnostic evaluation of PCNSL. The case reports a 44-year-old man who presented with clinical symptoms including persistent neck pain, upper limb weakness, blurred vision in the left eye. His Aquaporin4 antibody (AQP4 antibody) was slightly positive (1:10), and cervical spinal cord magnetic resonance imaging (MRI) showed the continuous segment and multifocal areas throughout cervical spinal cord with obvious homogenous enhancement, leading to an initial misdiagnosis of NMO. His symptoms progressively improved after steroid pulse treatment, but worse after steroid tapering. Following magnetic resonance spectroscopy (MRS) and positron emission tomography (PET) examinations, PCNSL should be firstly considered. Immunohistochemical analysis confirmed this diagnosis. After undergoing chemotherapy, the patient’s lesion area was reduced. Unfortunately, the patient ultimately died after being hospitalized for 9 months. Since PCNSL, especially in the spinal cord, is uncommon, its neuroimaging appearance could be misdiagnosed with other conditions, such as NMO, when there is positive expression of AQP4 antibody. Special attention should be made to the clinical symptoms and follow-up brain and spinal MRI as well as histopathologic examination are recommended for early diagnosis and treatment.
Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial.
This clinical trial (NCT05347641) evaluated efficacy and safety of penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in patients with newly diagnosed (ND) primary central nervous system lymphoma (PCNSL). Patients received an induction treatment of six cycles of Pen-RMA every 3 weeks. Patients younger than 60 years who achieved at least partial remission (PR) underwent autologous stem cell transplantation (ASCT), followed by 8 cycles of penpulimab as maintenance therapy. For patients over 60 years or not eligible for ASCT who achieved complete remission (CR) after induction therapy received 8 cycles of penpulimab as maintenance treatment, and those who achieved PR were treated with whole brain radiotherapy (WBRT) combined with 8 cycles of penpulimab. Patients who achieved stable disease (SD) or progressive disease (PD) were withdrawn from this study. The primary endpoint was 2-year progression-free survival (PFS). Between April 2022 and December 2023, twenty-six ND-PCNSL patients were enrolled, and 23 patients were included in the intention-to-treat analysis. The median age was 65 (38‒74) yr. The overall response rate (ORR) and CR rate after the induction therapy were 95.7% and 91.3%, respectively. At a median follow-up of 29.4 months, the median PFS and overall survival (OS) were not reached. 2-year PFS and OS were 70.7% and 75.0%, respectively. The most frequent treatment-related adverse events were leukopenia, anemia, neutropenia, and thrombocytopenia. Grade 3 or worse treatment-related adverse events occurred in 7 (30.4%) of 23 patients. Cerebrospinal fluid (CSF) circulating-tumor DNA (ctDNA) monitoring was performed in 13 patients with imaging CR and 1 with PR after induction treatment. Among them, 8 had CSF ctDNA clearance while 6 were positive. Overall, Pen-RMA regimen demonstrated encouraging antitumor activity with a manageable toxicity in PCNSL.
Primary central nervous system lymphoma: Evolving treatment strategies to achieve improved long-term disease control.
ObjectiveDespite high initial response rates to chemotherapy, long-term disease control in primary central nervous system lymphoma (PCNSL) remains challenging, with high relapse rates and no universally accepted standard for induction or consolidation therapy. This review discusses current strategies, new advancements and clinical trial results for PCNSL.Data SourcesAn extensive Medline, Embase and Cochrane search of peer-reviewed sources reporting on pharmacotherapy of PCNSL was performed (1/1/2000-12/31/2025). Analysis of original research including clinical trial results, retrospective series and other reports were included in this review.Data SummaryThis review summarizes the current understanding of PCNSL, including epidemiology, clinical presentation, diagnostic evaluation, and response assessment, with a focus on pharmacologic management. We discuss modern induction strategies centered on high-dose methotrexate (HD-MTX) and rituximab, consolidation approaches including reduced-dose whole-brain radiotherapy (WBRT), autologous stem cell transplantation (ASCT), and maintenance strategies, as well as emerging therapies for relapsed or refractory disease. A case of a 76-year-old patient achieving sustained remission exceeding seven years following rituximab plus HD-MTX induction and consolidative therapy is presented to illustrate the potential for durable disease control and even cure. These data underscore the importance of individualized treatment selection based on patient age, fitness level and response to induction and highlight that lasting remission is achievable in select patients with optimized, multimodal therapy.ConclusionsDespite its rarity, PCNSL remains a therapeutically challenging malignancy. HD-MTX-based chemotherapy remains the cornerstone of first-line treatment, and the addition of rituximab has been associated with more sustained responses. Although relapses are not uncommon, long-term remission is achievable. Clinical trials of newer agents, alone or added to a backbone of traditional chemotherapy, are warranted in the 1st and subsequent lines of therapy. Continued prospective research and international collaboration are essential to integrate precision oncology to the bedside of patients with PCNSL.
Publicações recentes
Successful re-infusion of hepatitis E contaminated stem cells during autologous stem cell transplantation with ribavirin prophylaxis.
Early diagnosis and management of primary vitreoretinal lymphoma with non-radiologic leptomeningeal involvement using MYD88 Leu265Pro variant analysis.
Comparative Outcomes of Consolidation Strategies After R-MVP Induction in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
Advances in first-line treatment for primary central nervous system lymphoma: highlights from the 2025 ASH annual meeting.
Primary Central Nervous System Lymphoma with Central Diabetes Insipidus and Hypopituitarism: Diagnostic Pitfalls in the "Ghost Tumor" with Steroid-induced Lymphocytolysis.
📚 EuropePMC1.986 artigos no totalmostrando 197
Secondary graft failure after autologous stem cell transplantation for primary central nervous system lymphoma responds to ciclosporin and eltrombopag.
Leukemia & lymphomaPrimary central nervous system lymphoma: Evolving treatment strategies to achieve improved long-term disease control.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy PractitionersRadiomics-based differentiation between glioblastoma and primary central nervous system lymphoma: CT vs MRI.
Cancer imaging : the official publication of the International Cancer Imaging SocietyCystatin C regulates cell division in primary central nervous system lymphoma.
Scientific reportsTreatment initiation by positive liquid biopsy alone in primary central nervous system lymphoma: A retrospective analysis of a multi-institutional study.
Neuro-oncology advancesThe Regulation of Vasomotor and Cardiorespiratory Pulsations Is Disrupted in Primary Central Nervous System Lymphoma: A Case-Control fMRI Study.
Human brain mappingFotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysis.
Therapeutic advances in medical oncologyEffective high-dose methotrexate toxicity reversal using fixed-dose glucarpidase in obese patients: a case series.
Journal of medical case reportsHIV-associated lymphoproliferative disorders: Single-center experience.
MedicineImproving MRI-based differentiation of brain metastasis, glioblastoma, and primary CNS lymphoma using deep learning.
NeuroradiologyMovement disorders due to primary central nervous system lymphoma: An illustrative case and systematic literature review.
Revue neurologiqueReal-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study.
Journal of neuro-oncologyAn Update on Treatments for Recurrent Primary Central Nervous System Lymphoma.
Current oncology reportsPrimary Dural Diffuse Large B-Cell Lymphoma: A Report of a Rare Case and Review of the Literature.
CureusSuperiority of high-dose cytarabine-based mobilisation over cyclophosphamide or plerixafor in primary CNS lymphoma.
Annals of hematologyKPT-8602 combined with IFN-γ released ZBP1-PANoptosome to inhibit the progression of primary central nervous system lymphoma.
Experimental cell researchPrimary Central Nervous System Lymphoma With Testicular and Prostatic Involvement: A Case Report.
CureusBrain Lesions Associated with Human Immunodeficiency Virus Infection in the Antiretroviral Therapy Era: A Single-center Experience in Japan.
Neurologia medico-chirurgicaAdvances in liquid diagnostics for primary central nervous system lymphoma: a narrative review.
Neurologia i neurochirurgia polskaA case report: primary central nervous system lymphoma misdiagnosed as neuromyelitis optica.
BMC neurology[Coexistence of primary central nervous system lymphoma and cerebral toxoplasmosis in a patient with advanced HIV infection and negative serology].
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de QuimioterapiaTime matters: The prognostic impact of diagnostic delay on survival in primary central nervous system lymphoma-a single-center, retrospective real-world study.
Neuro-oncology advancesExosomal ANGPTL2 in cerebrospinal fluid as a novel prognostic biomarker for primary central nervous system lymphoma.
Frontiers in immunologyPrognostic Assessment of Surgical Strategies and Extent of Resection in Methotrexate-Based Treatment for Primary Central Nervous System Lymphoma: A Propensity-Matched Analysis.
World neurosurgeryConsolidation reduced-dose whole-brain radiation therapy with response-adapted boost in older patients with newly diagnosed primary central nervous system lymphoma.
Journal of neuro-oncologyClinical Characteristics and Prognosis of Primary Central Nervous System Lymphoma: A Retrospective Analysis.
CancersStrategies for Managing Toxicities With High-Dose Methotrexate in Haematological Malignancies: Lessons From Clinical Cases.
Clinical case reportsPenpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial.
Blood cancer journalA 62-Year-Old-Man With Severe Daytime Sleepiness After Primary Central Nervous System Lymphoma.
ChestUse of Glucarpidase for Methotrexate-Induced Nephrotoxicity During the Treatment of Primary Central Nervous System Lymphoma.
CureusIncidence and Management of Tirabrutinib-associated Cutaneous Adverse Events: A Case Series.
Yakugaku zasshi : Journal of the Pharmaceutical Society of JapanComposite lymphoma comprising adult T-cell leukemia/lymphoma and Epstein-Barr virus-positive primary central nervous system lymphoma.
Journal of clinical and experimental hematopathology : JCEHZanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.
British journal of haematologyDiagnostic utility of cerebrospinal fluid IgG index, 24-hour IgG synthesis rate, and immunophenotyping in primary central nervous system large B-cell lymphoma: A case report.
MedicineDifferentiation of high-grade glioma and primary central nervous system lymphoma based on imaging heterogeneity scoring system.
Neurosurgical reviewDevelopment and validation of multiple machine learning algorithms for differentiating primary central nervous system lymphoma from adult-type diffuse glioma: an interpretable and multicenter study.
Frontiers in oncologyPrimary dural lymphoma of the chronic lymphocytic lymphoma/small lymphocytic lymphoma-mimicking meningioma: illustrative case.
Journal of neurosurgery. Case lessonsIbrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine (R-MVP/i) for newly diagnosed primary CNS lymphoma (PCNSL).
Neuro-oncologyInduction chemotherapy with methotrexate, nimustine, and procarbazine for primary CNS lymphoma in the elderly: a retrospective evaluation of safety and efficacy.
Journal of neuro-oncologyEarly Diagnostic Value of Contrast-Enhanced MRI in Distinguishing Toxoplasmic Encephalitis from CNS Lymphoma: A Case Report of AIDS with Seronegative Toxoplasmosis.
Journal of the International Association of Providers of AIDS CareEducational and regional differences in population-based incidence and survival of primary central nervous system lymphoma in Finland.
BMC cancerStereotactic Radiosurgery for Primary Central Nervous System Lymphoma: Results From the International Radiosurgery Research Foundation.
NeurosurgeryBehavioral Changes as the Initial Presentation of Primary Central Nervous System Lymphoma: A Case Report.
CureusIt Is Not Always Metastasis: A Case Report of a Primary Nervous System Anaplastic Large Cell Lymphoma and the Relevance of Brain Biopsy.
CureusPrimary central nervous system lymphoma in children: Insights from the three-year experience at the largest public-sector pediatric oncology center in Pakistan.
Pakistan journal of medical sciencesHigh-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry.
CancersMultifocal anaplastic astrocytoma mimicking primary central nervous system lymphoma: A case report.
MedicineA first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma.
CancerLINNDA: Lymphoma identification through neural network detection aid.
iScienceNew biomarkers for the diagnosis of primary central nervous system lymphoma in CSF: A multicenter retrospective cohort study.
Neuro-oncology advancesEvaluation of programmed cell death ligand-1 expression in primary central nervous system lymphoma using whole-tumor histogram analysis of multiparametric MRI: implications for immunotherapy selection.
Frontiers in immunologyPrimary Central Nervous System Lymphoma: A Case Report of the Neurological Great Mimicker.
CureusA Durable Remission Following Pseudo-Progression in Tirabrutinib Treatment for Relapsed Primary Central Nervous System Lymphoma: A Case Study.
Case reports in hematologyPrognostic impact of procarbazine in R-MPV followed by reduced-dose whole-brain radiotherapy and cytarabine for primary central nervous system lymphoma.
Leukemia & lymphomaSuccessful combined treatment for primary central nervous system lymphoma with massive hemorrhage: Illustrative case.
Surgical neurology international[Autologous hematopoietic stem cell transplantation with TBE conditioning in patients with primary central nervous system lymphoma].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiReal-world survival, cognitive, and quality of life outcomes of methotrexate/ifosfamide plus whole brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
Therapeutic advances in hematologyIntraocular Lymphoma: A Review.
Journal of ophthalmic & vision researchA retrospective analysis of autologous stem cell transplantation conditioning with reduced-dose busulfan/thiotepa for patients with central nervous system lymphomas at a single institution.
International journal of hematologyTirabrutinib rechallenge achieved complete response for recurrent primary central nervous system lymphoma: illustrative case.
International cancer conference journalSuccessful treatment of primary intramedullary spinal cord lymphoma based on the molecular diagnosis of a MYD88 mutation in the cerebrospinal fluid: a case report.
International cancer conference journalPhase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma.
Blood and lymphatic cancer : targets and therapyEffectiveness and safety of orelabrutinib combined with rituximab, temozolomide, methotrexate, and cytarabine in intensive chemotherapy-unfit patients with PCNSL in China.
European journal of medical researchPrebiopsy Steroids and Diagnostic Yield in Patients With Diffuse Large B-Cell Lymphoma.
JAMA network openRole of Geriatric Assessment Scores as Predictors of Intensive Therapy Feasibility and Survival in Elderly Patients with Primary CNS Lymphoma.
CancersMultiple primary central nervous system lymphoma in the ventricular system and interpeduncular cistern: A case report.
Oncology lettersA Case Report of HIV-Associated Pituitary Lymphoma and Review of the Literature.
Clinical case reportsDevelopment and validation of a convolutional neural network for automatic differentiation of primary central nervous system lymphoma and glioblastoma.
Cancer imaging : the official publication of the International Cancer Imaging SocietyA Novel Prognostic Model for Primary CNS Lymphoma Incorporating Clinico-Laboratory Parameters.
Neuro-oncologyElevated polyglutamylation and tau phosphorylation levels are associated with cognitive impairment at diagnosis in patients with primary central nervous system lymphoma.
Alzheimer's research & therapy[Primary lymphoma of the central nervous system].
Arkhiv patologiiOutcomes of de novo primary central nervous system lymphoma using the MATRix regimen for induction followed by thiotepa-based conditioning: a GELTAMO analysis.
Bone marrow transplantationLength of hospital stay and outcome in primary central nervous system lymphoma: a French retrospective multicentric study.
Annals of hematologyEfficacy and Limitations of Flow Cytometry for the Rapid Diagnosis of Primary Central Nervous System Lymphoma.
CancersGenomic landscape and molecular subtypes of primary central nervous system lymphoma.
Blood cancer journalDiagnostic Potential of Cerebrospinal Fluid Biomarkers in Diagnosis of Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis.
Annals of Indian Academy of NeurologyElectron Density and Effective Atomic Number as Quantitative Biomarkers for Differentiating Malignant Brain Tumors: An Exploratory Study with Machine Learning.
Tomography (Ann Arbor, Mich.)Outcomes for Primary Central Nervous System Lymphoma from a Single Institution.
Hematology reportsPrimary Central Nervous System Lymphoma Associated With Immune Deficiency and Dysregulation: Challenges in Treatment and Management.
CureusA Case of Primary Central Nervous System Lymphoma Mimicking a Demyelinating Disorder: From Steroids to Stem Cell Transplant.
CureusPrimary central nervous system lymphoma mimicking an otitis media complication: an unusual presentation with sigmoid sinus thrombosis.
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck SurgeryClonal identification and homology differentiate primary central nervous system lymphoma from non-central nervous system lymphoplasmacytic lymphoma: a case report.
Journal of medical case reportsOrelabrutinib plus reduced-dose whole brain radiotherapy in elderly primary central nervous system lymphoma: a case report.
Frontiers in oncology[The Efficacy and Safety of Modified Thiotepa-Based Conditioning Followed by Autologous Stem Cell Transplantation in Primary CNS Lymphomas].
Zhongguo shi yan xue ye xue za zhiHypothalamic-Pituitary Axis Involvement in Primary Central Nervous System Lymphoma: A Systematic Review.
The Journal of clinical endocrinology and metabolismChemotherapy-Free Salvage Therapy with Rituximab, Lenalidomide, and Poseltinib in Relapsed or Refractory Primary Central Nervous System Lymphoma: A Multi-Center, Phase II Study.
Cancer research and treatmentPrimary Dural Diffuse Large B-Cell Lymphoma: A Case Report.
JMA journalRole of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.
Acta neurologica Belgicau-LINNDA: A protocol for user-optimized lymphoma identification through neural network detection aid.
STAR protocolsMass cytometric analysis of circulating immune landscape in primary central nervous system lymphoma.
Frontiers in immunologyMulticenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma.
Neuro-oncologyInterpretable radiomics-based machine learning model for differentiating glioblastoma from primary central nervous system lymphoma using contrast-enhanced T1-weighted imaging.
Scientific reportsPlain language summary about tirabrutinib in relapsed/refractory primary central nervous system lymphoma.
Future oncology (London, England)Evaluation of Prognostic Factors in Primary Central Nervous System Lymphomas: A Single-Center Study.
Turkish neurosurgeryPreoperative multiparameter MRI-based prediction of Ki-67 expression in primary central nervous system lymphoma.
Precision radiation oncologyStudy of plasma exosomal miRNAs as novel biomarkers for differentiating primary central nervous system lymphoma and glioblastoma.
BMC cancerSellar-suprasellar pituitary lymphoma mimicking pituitary adenoma: a case report with literature review.
Journal of surgical case reportsClinical utility of repeat brain biopsy in recurrent or refractory primary CNS lymphoma - a diagnostic dilemma.
Journal of neuro-oncologyLong-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results.
Hematological oncologySpecific Marker Gene Analysis for Primary Central Nervous System Lymphoma Based on Methylation Difference and Development of Detection Primers.
Brain and behavior[Clinical characteristics and prognosis of 52 patients with primary central nervous system lymphoma].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiTargeting PD-L1 for PCNS-DLBCL: from molecular effects to clinical translation.
Frontiers in immunologyClinical characteristics and prognosis of ventricular primary central nervous system lymphoma: a case series and literature review.
Chinese neurosurgical journalPopulation pharmacokinetics of high-dose methotrexate and 7-hydroxy methotrexate in Chinese adults with primary central nervous system lymphoma.
British journal of haematologyMagnetic Resonance Spectroscopy in the Evaluation of Biopsy-Indeterminate Primary Central Nervous System Lymphoma: A Case Report.
CureusLenalidomide-rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach.
Annals of hematologyCorticosteroid Use Before Stereotactic Brain Biopsy for Suspected Lymphoma.
NeurosurgeryLymphomatosis cerebri presenting with rapidly progressive parkinsonism and Holmes tremor: a case report.
BMC neurologyUncertainty-aware ensemble of foundation models differentiates glioblastoma from its mimics.
Nature communicationsCase Report: Chronic subdural hematoma secondary to primary central nervous system lymphoma.
Frontiers in surgeryThe role of surgical resection and stereotactic radiosurgery in PCNS-DLBCL: a retrospective analysis of clinical benefits.
International journal of surgery (London, England)Automatic Segmentation of Primary Central Nervous System Lymphoma at Clinical Routine Postcontrast T1-weighted MRI.
Radiology. Imaging cancerA Case of Relapsed/Refractory Primary Central Nervous System B-Cell Lymphoma with Renal Insufficiency Successfully Treated with Linperlisib.
Turkish journal of haematology : official journal of Turkish Society of HaematologyThe Landscape of Primary Central Nervous System Lymphoma (PCNSL): Clinicopathologic and Genomic Characteristics and Therapeutic Perspectives.
CancersMeta-analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary central nervous system lymphoma.
CancerCase Report: Effective methotrexate removal by combined hemodialysis and polymeric resin hemoadsorption.
Frontiers in nephrologyDiagnostic Performance of CSF Interleukin-10 in Primary Central Nervous System Lymphoma: A Retrospective Study.
CureusCo-existence of Primary Glioma and Lymphoma: An Unusual Case Report.
NMC case report journalManagement of primary central nervous system lymphoma and coexisting heart failure with reduced ejection fraction: a narrative review.
Cardio-oncology (London, England)Radiation Retinopathy After Whole-Brain Radiotherapy in a Patient With Pineal Gland Tumor.
Journal of vitreoretinal diseasesNMDAR-Antibody Encephalitis Diagnosed With Primary Central Nervous System Lymphoma: A Case Series.
Annals of clinical and translational neurologyBloodstream Infection Caused by Mycobacterium neoaurum in a Primary Central Nervous System Lymphoma Patient with Toxic Epidermal Necrolysis.
Internal medicine (Tokyo, Japan)Multiparametric MRI for differential diagnosis of primary central nervous system lymphoma and atypical glioblastoma: an analysis incorporating DWI, DCE-MRI, and contrast agent preload DSC-PWI.
BMC medical imagingThe Role of Percentage Signal Recovery (PSR) in MRI Perfusion for the Diagnosis of Primary Central Nervous System Lymphoma.
CureusPrimary Central Nervous System B-Cell Lymphoma Presenting with Fluctuating Basal Ganglia and Cortical Lesions.
Journal of the Belgian Society of RadiologyTumor Habitats Based on Multiparametric MRI Distinguish Atypical Glioblastoma From Primary Central Nervous System Lymphoma: Imaging-Pathologic Correlation.
Journal of magnetic resonance imaging : JMRIRisk factors associated with high-dose methotrexate induced toxicities in primary central nervous system lymphoma.
Frontiers in pharmacologyPrimary central nervous system lymphomas in three "blue books" and correlation of recently defined primary large B-cell lymphoma of immune-privileged sites: Single-center experience.
Indian journal of pathology & microbiologyClinicopathological Significance of Tumor-Infiltrating T Lymphocytes and Macrophages in Primary Large B-Cell Lymphoma of Immune-Privileged Sites.
Cancer research and treatmentLiquid Biopsy and Epigenetic Signatures in AML, ALL, and CNS Tumors: Diagnostic and Monitoring Perspectives.
International journal of molecular sciencesSecondary Versus Recurrent Central Nervous System Lymphoma: Evaluating the Similarities and Differences in a Single-Institution Cohort.
CureusCase Report: CAR-T therapy for primary cerebellar ALK-negative anaplastic large cell lymphoma.
Frontiers in immunologyClinical characteristics and prognosis of primary central nervous system lymphoma in China: a single-center retrospective analysis of 325 patients.
Leukemia & lymphomaHistogram analysis based on DTI and NODDI for differentiating atypical high-grade glioma from primary central nervous system lymphoma.
Frontiers in neurologyNew treatment strategies for primary central nervous system lymphoma.
Current opinion in oncologyMolecular Characterization and Therapeutic Implications of MYD88 and CDKN2A in Primary CNS Lymphoma.
Anticancer researchPrognosticating salvage stereotactic radiosurgery outcomes in relapsed primary central nervous system lymphoma: A machine learning-driven decision tree analysis.
Translational oncologyExploration of the Optimal Treatment Modality for Vitreoretinal Lymphoma: A PRISMA Compliant Meta-Analysis and Systematic Review.
Cancer medicineThe Diagnostic Yield of Cerebrospinal Fluid Analysis for the Diagnosis of Primary Central Nervous System Lymphoma: A Systematic Review.
CancersA nomogram for predicting the diagnosis of central malignant tumors based on preoperative clinical characteristics and laboratory indicators: a diagnostic study.
International journal of surgery (London, England)Comparative analysis of the tumor microenvironment in primary CNS and testicular large B-cell lymphomas using digital image analysis and its implications for immunotherapy.
Human pathologyPDL1 Gene Gain Predicts an Unfavorable Prognosis in HIV-Positive Primary Central Nervous System Lymphoma.
Current oncology (Toronto, Ont.)Case report: diagnostic challenges of primary central nervous system anaplastic large cell lymphoma, ALK-positive.
Child's nervous system : ChNS : official journal of the International Society for Pediatric NeurosurgeryProgrammed death inhibitors in CNS B-cell lymphoma: A literature review.
Blood reviewsReal-World Efficacy and Safety of the Combination of Rituximab, Lenalidomide, and Ibrutinib in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood TransfusionVasomotor fluctuations are increased in primary central nervous system lymphoma: a case-control study with fast functional MRI.
Brain communicationsDiagnostic Odyssey: Primary CNS Lymphoma (Lymphoma Cerebri) Presenting as Rapidly Progressive Dementia.
Case reports in hematologyCirculating tumor DNA in B cell lymphomas.
Current opinion in oncologyClinical Characteristics, Prognostic Risk Factors, and Primary Treatment for Elderly Patients with Primary Central Nervous System Lymphoma: A Seer Database-Based Research.
Blood and lymphatic cancer : targets and therapyDexamethasone-associated regression of glioblastoma.
Surgical neurology internationalRituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma.
LeukemiaClinical Predictors and Recurrence Characteristics Following Radiotherapy for Primary Central Nervous System Lymphoma: A Retrospective Cohort Study.
CancersWhole-Eye Radiation for the Local Control of Choroidal Lymphoma in Primary Central Nervous System Lymphoma: A 14-Year Case Study.
CureusUltra-sensitive detection of microRNA in intraocular fluid using optical fiber sensing technology for central nervous system lymphoma diagnosis.
Reports on progress in physics. Physical Society (Great Britain)Meeting Report From the 2024 Symposium on IRAK4 in Cancer: Highlights and Clinical Updates.
Clinical lymphoma, myeloma & leukemiaOutcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma.
Blood neoplasiaClinically probable paraneoplastic vasculitic peripheral neuropathy in primary central nervous system lymphoma: a case report.
BMC neurologyMolecular diagnosis of vitreoretinal lymphoma.
Taiwan journal of ophthalmologyImmune Checkpoint Molecule Expression, 9p24.1 Gene Alterations, and Tumor Microenvironment of Primary Central Nervous System Lymphomas and Their Clinical Relevance.
Applied immunohistochemistry & molecular morphology : AIMMPlasmablast-like lymphoma cells as a distinct subpopulation confer multidrug resistance in PCNSL.
Neuro-oncologyPrimary central nervous system lymphoma: Predictors of response to induction therapy and patterns of progression.
Neuro-oncology advancesRefinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI.
Neuro-oncology advancesDiffusion-weighted imaging and susceptibility-weighted imaging in differentiating ring-enhancing primary central nervous system lymphoma from infections.
The neuroradiology journalPrimary central nervous system lymphoma: A 7 years single-center experience.
Neuro-ChirurgieA Case of Primary Central Nervous System T-cell Lymphoma of the Spinal Cord Detected by 18 F-FDG PET/CT.
Clinical nuclear medicineComparison of survival and progression after focal- or whole brain radiotherapy in patients with primary CNS lymphoma - Results from a large multicenter analysis of the German Society of Radiation Oncology's Neuro-Radio-Oncology Working Group (DEGRO AG-NRO).
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyLarge B-cell Lymphoma With Interferon Regulatory Factor 4 Rearrangement Presenting as a Primary Central Nervous System Lymphoma in the Brain.
CureusIdentifying risk factors for methotrexate-induced acute kidney injury despite full prevention in patients with primary central nervous system lymphoma.
Toxicology and applied pharmacologyClinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study.
Frontiers in immunologyRadiomics-Based Differentiation of Primary Central Nervous System Lymphoma and Solitary Brain Metastasis Using Contrast-Enhanced T1-Weighted Imaging: A Retrospective Machine Learning Study.
Academic radiologyPopulation pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
Frontiers in pharmacologySingle-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma.
Blood neoplasiaNovel Therapies in Primary Central Nervous System Lymphoma.
Clinical pharmacology : advances and applicationsThe activation of the NF-κB p65/PD-L1 signaling pathway in AIDS-related PCNSL is related to TNF-α and IFN-γ but not to MYD88 and CD79B mutations.
Pathology, research and practicePrimary Diffuse Large B-Cell Lymphoma of the Central Nervous System-Outcomes in Finland: A Nationwide Population-Based Study.
EJHaemLiquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside.
International journal of molecular sciencesOrelabrutinib combined with rituximab and high-dose methotrexate as induction therapy in newly diagnosed primary central nervous system lymphoma.
Investigational new drugsPost-marketing surveillance of tirabrutinib in 189 patients with r/r primary central nervous system lymphoma.
Future oncology (London, England)OCT4 and Nestin Expression in the Microenvironment of Primary Central Nervous System Lymphomas.
International journal of hematology-oncology and stem cell researchComplex Differential Diagnosis Between Cerebral Toxoplasmosis and Primary CNS Lymphoma in Immunocompromised Patients: The Value of Brain Biopsy.
Turkish neurosurgeryDiagnostic Challenges in an Elderly Patient With Cognitive Decline and an Incidental Brain Mass.
CureusAccumulation of N-Isopropyl-p(123I)iodoamphetamine on Single-Photon Emission Computed Tomography Between Immunosuppressed and Non-immunosuppressed Patients With Primary Central Nervous System Lymphoma.
CureusEfficacy and safety of the R2-MTX regimen in primary central nervous system lymphoma (PCNSL): a single-center retrospective analysis.
Journal of cancer research and clinical oncologyEstablishment and evaluation of an automatic multi?sequence MRI segmentation model of primary central nervous system lymphoma based on the nnU?Net deep learning network method.
Oncology lettersMetabolic pathway alterations in cerebrospinal fluid as diagnostic biomarkers for primary central nervous system lymphoma.
Clinica chimica acta; international journal of clinical chemistryMild Metabolism Increase on Posttreatment 18 F-FDG PET may Indicate Recurrence of Primary CNS Lymphoma.
Clinical nuclear medicineThe "purfling sign": a new imaging marker for the diagnosis of primary CNS lymphoma.
La Radiologia medicaRole of Radiotherapy in PCNSL within the Current Therapeutic Landscape: a Comprehensive Review.
Current treatment options in oncologyDevelopment and validation of a preoperative magnetic resonance imaging-based and machine learning model for the noninvasive differentiation of intracranial glioblastoma, primary central nervous system lymphoma and brain metastases: a retrospective analysis.
Frontiers in oncologyPrimary vitreoretinal lymphoma: diagnosis, treatment, and prognosis-a review of current knowledge and future directions.
Blood science (Baltimore, Md.)Prediction of early recurrence in primary central nervous system lymphoma based on multimodal MRI-based radiomics: A preliminary study.
European journal of radiologyA Natural Course From Primary Intraocular Lymphoma to Brain Lymphoma in Four Years According to Patient's Choice.
CureusProspective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma.
Blood cancer journalSafety and efficacy of programmed cell death-1 inhibitors in relapsed immune-privileged site lymphoma: A systematic review and meta-analysis.
PloS oneWhole brain radiotherapy combined with CART-cell therapy for relapsed/refractory central nervous system B-cell lymphoma.
Annals of hematologyPFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma.
Journal of hematology & oncologyMachine Learning-Enhanced Cerebrospinal Fluid N-Glycome for the Diagnosis and Prognosis of Primary Central Nervous System Lymphoma.
Journal of proteome researchAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Linfoma primário do sistema nervoso central.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Linfoma primário do sistema nervoso central
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Ainda não achamos doenças com sintomas parecidos o suficiente.
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- The Regulation of Vasomotor and Cardiorespiratory Pulsations Is Disrupted in Primary Central Nervous System Lymphoma: A Case-Control fMRI Study.
- KPT-8602 combined with IFN-γ released ZBP1-PANoptosome to inhibit the progression of primary central nervous system lymphoma.
- A case report: primary central nervous system lymphoma misdiagnosed as neuromyelitis optica.
- Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial.
- Primary central nervous system lymphoma: Evolving treatment strategies to achieve improved long-term disease control.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners· 2026· PMID 41841431mais citado
- Successful re-infusion of hepatitis E contaminated stem cells during autologous stem cell transplantation with ribavirin prophylaxis.
- Early diagnosis and management of primary vitreoretinal lymphoma with non-radiologic leptomeningeal involvement using MYD88 Leu265Pro variant analysis.
- Comparative Outcomes of Consolidation Strategies After R-MVP Induction in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
- Advances in first-line treatment for primary central nervous system lymphoma: highlights from the 2025 ASH annual meeting.
- Primary Central Nervous System Lymphoma with Central Diabetes Insipidus and Hypopituitarism: Diagnostic Pitfalls in the "Ghost Tumor" with Steroid-induced Lymphocytolysis.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:46135(Orphanet)
- MONDO:0002571(MONDO)
- GARD:9318(GARD (NIH))
- Busca completa no PubMed(PubMed)
- Artigo Wikipedia(Wikipedia)
- Q3246818(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
